Region Skane Helsingborg Hospital

The Hematology Department at Helsingborg Hospital is advancing treatment options for bacterial infections by evaluating novel antibiotic regimens and preventive vaccines.

• Alternative antibiotics for multidrug‑resistant urinary tract infections
• Prevention of invasive Escherichia coli disease in older adults
• Reducing recurrence of Clostridioides difficile infection with monoclonal antibodies

Ongoing studies aim to improve patient outcomes and limit antimicrobial resistance, positioning the site as a leader in infection research.

Researchers at the Helsingborg site are investigating innovative therapies for cardiovascular conditions, targeting heart failure and acute coronary events.

• Evaluating balcinrenone/dapagliflozin versus dapagliflozin in heart failure with kidney impairment
• Assessing maridebart cafraglutide for cardiovascular morbidity in patients with atherosclerotic disease
• Self‑administered selatogrel for early treatment of suspected acute myocardial infarction

The trials focus on reducing hospitalization, cardiovascular death, and improving quality of life for high‑risk patients.

The department conducts studies on women’s reproductive health, emphasizing safer labour induction and management of urinary complications.

• Outpatient induction of labour compared with inpatient protocols
• Safety of step‑down oral antibiotics for febrile urinary tract infections caused by ESBL‑producing bacteria

These projects aim to enhance maternal outcomes while reducing hospital stays and antibiotic resistance.

Clinical investigations at Helsingborg focus on blood‑cell disorders, especially multiple myeloma and related malignancies.

• Comparing new monoclonal antibody combinations in relapsed or refractory multiple myeloma
• Evaluating etentamig as monotherapy for heavily pre‑treated multiple myeloma patients
• Assessing BCMA‑CD3 bispecific antibody therapy durability after response

The goal is to extend survival, achieve deeper remissions, and explore novel immunotherapy approaches.

The hospital’s oncology research targets solid and hematologic cancers, with a particular emphasis on innovative drug combinations.

• Tec‑Dara versus standard regimens for relapsed or refractory multiple myeloma
• Elranatamab versus lenalidomide in newly diagnosed multiple myeloma after transplant
• IberDd versus DVd regimen focusing on minimal residual disease negativity

These trials seek to improve response rates and provide new therapeutic options for patients with advanced disease.

Studies at the site address neurological disorders, including facial nerve palsy and severe viral lung infections with neurological implications.

• Cortisone versus placebo for acute facial nerve palsy in children
• Tozorakimab as adjunct therapy for severe viral lung infection requiring oxygen

The research aims to accelerate recovery, reduce complications, and explore anti‑inflammatory strategies.

The department evaluates interventions for critical clinical presentations such as hypotension and shock in emergency settings.

• Early initiated vasopressor therapy versus fluid resuscitation for non‑bleeding hypotensive patients
• Comparing penicillin‑susceptible Staphylococcus aureus bacteraemia treatments with benzylpenicillin and cloxacillin

Objectives include faster stabilization, reduced intensive care needs, and improved survival outcomes.

Research at Helsingborg targets serious respiratory infections, focusing on viral and bacterial etiologies.

• Tozorakimab for hospitalized patients with severe viral lung infection
• AZD5148 monoclonal antibody to prevent recurrent Clostridioides difficile infection

These studies aim to lower mortality, decrease need for mechanical ventilation, and prevent infection recurrence.

The hospital’s psychiatry program investigates novel approaches for mental health conditions, particularly schizophrenia and major depressive disorder.

• Rituximab versus placebo for improvement in schizophrenia spectrum disorder
• Long‑term safety and tolerability of NBI‑1065845 as adjunctive therapy in major depressive disorder
• Iclepertin safety follow‑up in participants with schizophrenia who completed prior studies

The trials seek to enhance symptom control, reduce relapse rates, and expand therapeutic options for patients.